{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:52:36Z","timestamp":1787068356350,"version":"build-2736575974"},"reference-count":31,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["22 2231 Pj"],"award-info":[{"award-number":["22 2231 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ume\u00e5 Comprehensive Cancer Consortium"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: High-risk prostate cancer is often treated with combined androgen deprivation therapy (ADT) and radiotherapy (RT). Blood biomarkers may enable treatments to be tailored to individual patients. Metabolomics, the study of small-molecule alterations in blood, is promising, and lipids are emerging as potential markers of poor prognosis. This study aims to investigate metabolic changes during prostate cancer treatment and their correlation to disease outcome. Methods: This study included 136 blood plasma samples from 35 patients with high-risk prostate cancer treated with RT and ADT, recruited from the Uppsala\/Ume\u00e5 Comprehensive Cancer Consortium (U-CAN) project. Blood samples were collected before, during, and after treatment and analyzed at Metabolon Inc. (Durham, NC, USA). To study differences in metabolic levels during treatment, three different sampling time points were considered: before ADT, in-between ADT and RT, and after RT. Both multivariate (orthogonal projections to latent structures, OPLS) and univariate analyses were performed, where statistical significance in combination with a large fold change was considered indicative of a substantial change. Results: Significant changes in metabolite levels were observed. Many of the significant metabolites for the whole course of treatment were also significant during ADT but not during RT, indicating that changes during ADT dominated the overall treatment. Changes were found to be especially common in steroids and fatty acids. Multivariate analysis revealed significant differences in metabolites between relapsing and non-relapsing patients. Among the significant metabolites were cholesterol and epiandrosterone. Conclusions: Metabolomics can identify biomarkers for prostate cancer treatment response and relapse. Further studies are needed to identify patterns and individual metabolites to personalize treatment strategies for prostate cancer.<\/jats:p>","DOI":"10.3390\/cancers17243993","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:15:08Z","timestamp":1765811708000},"page":"3993","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolomic Insights into Prostate Cancer Treatment and Relapse"],"prefix":"10.3390","volume":"17","author":[{"given":"Kristina","family":"Lundquist","sequence":"first","affiliation":[{"name":"Department of Chemistry, Ume\u00e5 University, 901 87 Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Antti","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Ume\u00e5 University, 901 87 Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7061-7255","authenticated-orcid":false,"given":"Camilla","family":"Thellenberg Karlsson","sequence":"additional","affiliation":[{"name":"Department of Diagnostics and Intervention, Ume\u00e5 University, 901 87 Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes from Phase III Randomized Controlled Trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","volume":"5","author":"Esteva","year":"2022","journal-title":"npj Digit. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/1055-9965.EPI-15-1223","article-title":"Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence","volume":"25","author":"Kelly","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/ijc.30903","article-title":"A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer","volume":"141","author":"Lin","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41391-021-00338-z","article-title":"Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer","volume":"24","author":"Lin","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/metabo3030552","article-title":"A review of applications of metabolomics in cancer","volume":"3","author":"Beger","year":"2013","journal-title":"Metabolites"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gonzalez-Covarrubias, V., Martinez-Martinez, E., and Del Bosque-Plata, L. (2022). The potential of metabolomics in biomedical applications. Metabolites, 12.","DOI":"10.3390\/metabo12020194"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrc1390","article-title":"Metabolic profiles of cancer cells","volume":"4","author":"Griffin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/1078-0432.CCR-08-1059","article-title":"Clinical applications of metabolomics in oncology: A review","volume":"15","author":"Spratlin","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.aca.2009.11.042","article-title":"Chemometrics in metabolomics\u2014A review in human disease diagnosis","volume":"659","author":"Madsen","year":"2010","journal-title":"Anal. Chim. Acta"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/0284186X.2017.1337926","article-title":"U-CAN: A prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden","volume":"57","author":"Glimelius","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"\u00c5berg, A.M., Bergstr\u00f6m, S.H., Thysell, E., Tjon-Kon-Fat, L.-A., Nilsson, J.A., Widmark, A., Thellenberg-Karlsson, C., Bergh, A., Wikstr\u00f6m, P., and Lundholm, M. (2021). High Monocyte Count and Expression of S100A9 and S100A12 in Peripheral Blood Mononuclear Cells Are Associated with Poor Outcome in Patients with Metastatic Prostate Cancer. Cancers, 13.","DOI":"10.3390\/cancers13102424"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41591-021-01266-0","article-title":"Plasma metabolites to profile pathways in noncommunicable disease multimorbidity","volume":"27","author":"Pietzner","year":"2021","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s11306-015-0818-3","article-title":"Constrained randomization and multivariate effect projections improve information extraction and biomarker pattern discovery in metabolomics studies involving dependent samples","volume":"11","author":"Jonsson","year":"2015","journal-title":"Metabolomics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0169-7439(87)80084-9","article-title":"Principal component analysis","volume":"2","author":"Wold","year":"1987","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cem.1006","article-title":"OPLS discriminant analysis: Combining the strengths of PLS-DA and SIMCA classification","volume":"20","author":"Rantalainen","year":"2006","journal-title":"J. Chemom."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/cem.1187","article-title":"CV-ANOVA for significance testing of PLS and OPLS\u00ae models","volume":"22","author":"Eriksson","year":"2008","journal-title":"J. Chemom."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Statist. Soc. B"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cam4.3016","article-title":"Metabolomic effects of androgen deprivation therapy treatment for prostate cancer","volume":"9","author":"Chi","year":"2020","journal-title":"Cancer Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Feng, L.R., Barb, J.J., Allen, H., Regan, J., and Saligan, L. (2021). Steroid Hormone Biosynthesis Metabolism Is Associated with Fatigue Related to Androgen Deprivation Therapy for Prostate Cancer. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.642307"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2014.01.048","article-title":"Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer","volume":"729","author":"Huang","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1158\/1078-0432.CCR-11-3209","article-title":"Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer","volume":"18","author":"Saylor","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1557988319876488","DOI":"10.1177\/1557988319876488","article-title":"Lipid Status During Combined Treatment in Prostate Cancer Patients","volume":"13","author":"Tukiendorf","year":"2019","journal-title":"Am. J. Mens Heal."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1210\/me.2005-0479","article-title":"Androgen activation of the sterol regulatory element-binding protein pathway: Current insights","volume":"20","author":"Heemers","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4111\/kju.2015.56.1.12","article-title":"Metabolic effects of androgen deprivation therapy","volume":"56","author":"Choi","year":"2015","journal-title":"Korean J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/1055-9965.EPI-14-0458","article-title":"Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database","volume":"23","author":"Allott","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Thysell, E., Surowiec, I., H\u00f6rnberg, E., Crnalic, S., Widmark, A., Johansson, A.I., Stattin, P., Bergh, A., Moritz, T., and Antti, H. (2010). Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014175"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/pcan.2015.58","article-title":"Association between statins and clinical outcomes among men with prostate cancer: A systematic review and meta-analysis","volume":"19","author":"Raval","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/annonc\/mdt077","article-title":"Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: A systematic review and meta-analysis","volume":"24","author":"Park","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2022.03.042","article-title":"Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302","volume":"170","author":"Wilson","year":"2022","journal-title":"Eur. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/3993\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:21:06Z","timestamp":1765812066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/24\/3993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":31,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cancers17243993"],"URL":"https:\/\/doi.org\/10.3390\/cancers17243993","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}